MDY Mdy Healthcare

RNS Number:4284N
Medisys PLC
6 July 2000
                             
                               
                          MEDISYS PLC
                  ("Medisys" or the "Group")
                               
      Futura Safety Syringe Receives FDA Market Approval
                               
Medisys announces that it has received notice from the US Food
and  Drug  Administration ("FDA") that the 3ml  model  of  its
Futura safety syringe has been approved for sale in the United
States.   FDA  market approval is a vital step in the  Group's
plans for the launch of the Futura syringe and enables Medisys
to proceed to the next stage of its launch programme.

The  Futura  safety syringe is an innovative  syringe  with  a
patented  elastomer based mechanism for retracting the  needle
following  use.  The syringe has been developed by Medisys  in
response  to  the  growing demand for medical safety  products
that  address  the  problem  of  needlestick  injury.   It  has
initially  been  developed in a 3ml model and  is  also  being
developed  in  1ml, 5ml and 10ml models.  The  Group  believes
that  the  design of the product will facilitate high  volume,
low  cost manufacture making it highly price competitive  with
existing safety syringes.

Futura    Medical   Inc.,   the   Medisys   subsidiary    with
responsibility   for   the  Futura   syringe,   is   currently
concentrating  on the implementation of its manufacturing  and
marketing  strategies  prior to the US market  launch  of  the
product in the final quarter of 2000.

Manufacturing Strategy

Futura  Medical  intends  to  use multiple  OEM  suppliers  to
manufacture  the Futura syringe, while retaining ownership  of
the   moulds  and  other  key  equipment  to  ensure   maximum
production flexibility and control over the production process
and  product  cost.  The OEM suppliers will  be  strategically
located  to  serve key geographic markets.  The  manufacturing
programme is on schedule, with the first full-scale production
plants  in Southern California and Singapore planned to  begin
pilot  production  before  the  end  of  this  calendar  year.
Production agreements for other geographic markets  are  under
negotiation and Medisys plans to have high volume capacity  in
place during the second half of 2001.

Sales & Marketing Strategy

Futura  Medical is also developing and implementing a detailed
sales  and  marketing plan for the Futura syringe.   The  plan
envisages a two-tier approach to maximise market and  customer
coverage.

A  strong in-house marketing team, assembled from some of  the
world's  leading medical products companies, is now  in  place
and the sales programme will utilise Futura Medical's existing
infrastructure which already has an established  customer  and
distributor base throughout the US.  Futura Medical will  also
explore  opportunities for strategic marketing alliances  with
large   healthcare  distributors  and  leading  suppliers   of
conventional disposable syringes.

David Wong, Chief Executive Officer said: "FDA market approval
was  a  critical milestone in the development  of  the  Futura
syringe.   The  Futura  Medical team is now  concentrating  on
achieving   production  scale-up  at  our  two   initial   OEM
manufacturing  sites  and  the first  multi-cavity  production
moulds   are  currently  being  cut.   We  believe  that   the
capability  to  supply US customers in  high  volume  will  be
crucial  to  our  future success and we have put  in  place  a
manufacturing strategy that will make this possible.

"Our  experienced in-house sales and marketing team at  Futura
is  well  advanced  in  its plans for the  market  launch  and
discussions  with  the  large suppliers  and  distributors  of
conventional  disposable syringes are  ongoing.   With  15  US
states  now  having passed legislation mandating  the  use  of
safety  syringes, the momentum for their adoption  is  growing
rapidly.   Medisys  is  committed  to  reducing  the  risk  of
needlestick injury through the successful introduction of cost
effective  alternatives and the Group remains well  placed  to
capitalise upon this very significant market opportunity."


Enquiries:

Medisys PLC                                      020 7663 5602
Michael Barry, Chief Financial Officer

Square Mile Communications                       020 7601 1000
Kevin Smith/Becky Jewers

MDY Healthcare (LSE:MDY)
Historical Stock Chart
Von Jun 2024 bis Jul 2024

MDY Healthcare (LSE:MDY)
Historical Stock Chart
Von Jul 2023 bis Jul 2024